GLP-1 Drugs May Improve Brain Outcomes After Aneurysm Treatment in Diabetic Patients
GLP-1 RA use was associated with improved clinical outcomes after endovascular treatment of unruptured brain aneurysms in patients with type 2 diabetes.
Quick Facts
What This Study Found
GLP-1 receptor agonist use was associated with improved clinical outcomes following endovascular treatment of unruptured intracranial aneurysms in type 2 diabetes patients.
Key Numbers
6,824 patients met criteria. 447 per group after propensity matching. No short/mid-term mortality differences. Long-term mortality significantly lower in GLP-1RA users.
How They Did This
Retrospective cohort study using the TriNetX multicenter database, comparing outcomes in T2D patients with unruptured intracranial aneurysms who used GLP-1 RAs versus those who did not.
Why This Research Matters
Brain aneurysm treatment carries risks of complications. If GLP-1 drugs provide neuroprotection during and after these procedures, they could improve outcomes for the millions of diabetic patients with aneurysms.
The Bigger Picture
This adds to mounting evidence that GLP-1 drugs have neuroprotective effects relevant to real-world brain procedures, beyond their established metabolic and cardiovascular benefits.
What This Study Doesn't Tell Us
Retrospective observational study — cannot prove causation. GLP-1 RA users may differ from non-users in health-seeking behaviors and overall health status.
Questions This Raises
- ?What specific neuroprotective mechanisms of GLP-1 RAs contribute to better aneurysm treatment outcomes?
- ?Should GLP-1 RA status be considered in pre-procedural planning for brain aneurysm treatment?
Trust & Context
- Key Stat:
- Improved clinical outcomes GLP-1 RA use was associated with better results after endovascular brain aneurysm treatment in diabetic patients
- Evidence Grade:
- Large retrospective database study — provides a meaningful signal but cannot establish causation. Prospective studies would be needed for definitive conclusions.
- Study Age:
- Published in 2025, exploring a novel neuroprotective application of GLP-1 drugs in cerebrovascular procedures.
- Original Title:
- GLP-1 Receptor Agonists and Clinical Outcomes after Endovascular Treatment of Unruptured Aneurysms in Type 2 Diabetes.
- Published In:
- Stroke (Hoboken, N.J.), 5(6), e001933 (2025)
- Authors:
- Perng, Pang-Shuo, Chang, Yu(3), Chuang, Ming-Tsung, Wong, Chia-En, Sun, Yuan-Ting, Wang, Hao-Kuang, Chi, Kuan-Yu, Lee, Jung-Shun, Wang, Liang-Chao, Huang, Chih-Yuan
- Database ID:
- RPEP-13025
Evidence Hierarchy
Looks back at existing records to find patterns.
What do these levels mean? →Frequently Asked Questions
Can GLP-1 drugs protect the brain?
Growing evidence suggests yes. GLP-1 receptors are present in the brain, and these drugs have anti-inflammatory and neuroprotective properties. This study found that GLP-1 RA use was associated with better outcomes after brain aneurysm treatment.
Should I start a GLP-1 drug before brain aneurysm treatment?
This study shows an association but does not prove that starting GLP-1 drugs specifically for this purpose would help. If you already take a GLP-1 drug for diabetes, the findings are reassuring. Discuss any treatment changes with your doctors.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13025APA
Perng, Pang-Shuo; Chang, Yu; Chuang, Ming-Tsung; Wong, Chia-En; Sun, Yuan-Ting; Wang, Hao-Kuang; Chi, Kuan-Yu; Lee, Jung-Shun; Wang, Liang-Chao; Huang, Chih-Yuan. (2025). GLP-1 Receptor Agonists and Clinical Outcomes after Endovascular Treatment of Unruptured Aneurysms in Type 2 Diabetes.. Stroke (Hoboken, N.J.), 5(6), e001933. https://doi.org/10.1161/SVIN.125.001933
MLA
Perng, Pang-Shuo, et al. "GLP-1 Receptor Agonists and Clinical Outcomes after Endovascular Treatment of Unruptured Aneurysms in Type 2 Diabetes.." Stroke (Hoboken, 2025. https://doi.org/10.1161/SVIN.125.001933
RethinkPeptides
RethinkPeptides Research Database. "GLP-1 Receptor Agonists and Clinical Outcomes after Endovasc..." RPEP-13025. Retrieved from https://rethinkpeptides.com/research/perng-2025-glp1-receptor-agonists-and
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.